A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight
                              in Young Adults with Schizophrenia, Schizoaffective, or Bipolar I Disorder Who are
                              Early in Their Illness
     Alkermes, Inc
     PI: Joseph McEvoy, M.D.
                           A randomized controlled trial of adjunctive tocilizumab in schizophrenia.
     NARSAD Independent Investigator Grant
     PI: Brian Miller, MD, PhD, MPH
                           A randomized controlled trial of adjunctive siltuximab in schizophrenia.
     Stanley Medical Research Institute
     PI: Brian Miller, MD, PhD, MPH
                         
                        
                           Insomnia, Autonomic Dysfunction, and Suicidal Ideation in Schizophrenia
      »Æ¹Ï¶ÌÊÓÆµ Pilot Study Research Program
      PI: Brian Miller, MD, PhD, MPH
                           Improving cognition via exercise in schizophrenia
     National Institute of Mental Health (NIMH)
     PI: Joseph McEvoy, MD
                           A multicenter, randomized, controlled trial of Brexpiprazole for the treatment of
                              co-occurring schizophrenia and substance use disorder
      Otsuka Pharmaceuticals
      PI: Joseph McEvoy, MD
                         
                        
                           Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
     National Institute of Mental Health (NIMH)
     PI: Joseph McEvoy, MD
                           Observational Study of LAIs in Schizophrenia
     Alkermes, Inc
     PI: Joseph McEvoy, M.D.
                           Phase II, A randomized, double-blind, multiple-dose, placebo-controlled study to evaluate
                              the safety and efficacy of BIIB104 in subjects with cognitive impairment associated
                              with schizophrenia
     Biogen MA, Inc.
     PI: Joseph McEvoy, MD
                         
                        
                           A randomized controlled trial of adjunctive tocilizumab in schizophrenia.
     NARSAD Independent Investigator Grant
     PI: Brian Miller, MD, PhD, MPH
                           A randomized controlled trial of adjunctive siltuximab in schizophrenia.
     Stanley Medical Research Institute
     PI: Brian Miller, MD, PhD, MPH
                           Clozapine, Insomnia, Hyperarousal, and Suicide in Schizophrenia
    »Æ¹Ï¶ÌÊÓÆµ Pilot Study Research Program
    PI: Brian Miller, MD, PhD, MPH
                         
                        
                           A phase II randomized, double-blind, placebo-controlled study to evaluate the efficacy,
                                 safety, and tolerability of orally administered BI 409306 during a 52-week treatment
                                 period as an early intervention in patients with attenuated psychosis syndrome.
     Boehringer Ingelheim Pharmaceuticals, Inc.
     PI: Joseph McEvoy, MD
                           Improving cognition via exercise in schizophrenia
     National Institute of Mental Health (NIMH)
     PI: Joseph McEvoy, MD
                           Metformin and Lorcaserin for weight loss in people with schizophrenia
     National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
     PI: Joseph McEvoy, MD
                         
                      
                     
                     
                        
                           A phase II, 12-week, randomized, double-blind, placebo-controlled, parallel study
                                 to evaluate efficacy, safety, tolerability, and pharmacokinetics of the three dose
                                 levels of TAK-831 in adjunctive treatment of adult patients with negative symptoms
                                 of schizophrenia
     Millennium Pharmaceuticals, Inc.
     PI: Joseph McEvoy, MD
                           Phase II, A randomized, double-blind, multiple-dose, placebo-controlled study to evaluate
                                 the safety and efficacy of BIIB104 in subjects with cognitive impairment associated
                                 with schizophrenia
     Biogen MA, Inc.
     PI: Joseph McEvoy, MD